دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Making inroads on sex and gender
doi : 10.1016/S2665-9913(22)00103-5
Volume 4, Issue 5, May 2022, Page e303
IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2
doi : 10.1016/S2665-9913(22)00090-X
Volume 4, Issue 5, May 2022, Pages e305-e307
Humoral response following SARS-CoV-2 vaccination: not all immunosuppressants are created equal
doi : 10.1016/S2665-9913(22)00066-2
Volume 4, Issue 5, May 2022, Pages e307-e308
No perfect therapy for the imperfect COVID-19 cytokine storm
doi : 10.1016/S2665-9913(22)00068-6
Volume 4, Issue 5, May 2022, Pages e308-e310
COVID-19 vaccine acceptance over time in patients with immune-mediated inflammatory rheumatic diseases
doi : 10.1016/S2665-9913(22)00009-1
Volume 4, Issue 5, May 2022, Pages e310-e313
Anti-citrullinated protein antibodies dominate the association of long-term outcomes and anti-modified protein antibodies in rheumatoid arthritis
doi : 10.1016/S2665-9913(22)00095-9
Volume 4, Issue 5, May 2022, Pages e316-e317
Latika Gupta: a thinker and a doer for myositis research
doi : 10.1016/S2665-9913(22)00105-9
Volume 4, Issue 5, May 2022, Page e319
Autoantibodies against interleukin-1 receptor antagonist in multisystem inflammatory syndrome in children: a multicentre, retrospective, cohort study
doi : 10.1016/S2665-9913(22)00064-9
Volume 4, Issue 5, May 2022, Pages e329-e337
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
doi : 10.1016/S2665-9913(22)00034-0
Volume 4, Issue 5, May 2022, Pages e338-e350
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
doi : 10.1016/S2665-9913(22)00044-3
Volume 4, Issue 5, May 2022, Pages e351-e361
Bilateral linear scleroderma with transition into progressive facial hemiatrophy
doi : 10.1016/S2665-9913(21)00185-5
Volume 4, Issue 5, May 2022, Page e374
